JAK2
MOLECULAR TARGETJanus kinase 2
JAK2 (Janus kinase 2) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting JAK2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Azauridine | 1.39 | 3 |
| 2 | Cladribine | 1.10 | 2 |
| 3 | Dasatinib | 1.10 | 2 |
| 4 | Methylene Blue | 0.69 | 1 |
| 5 | 2-Methoxyestradiol | 0.69 | 1 |
| 6 | Astemizole Antihistamine drug now withdrawn from | 0.69 | 1 |
| 7 | Azathioprine | 0.69 | 1 |
| 8 | Calcitriol | 0.69 | 1 |
| 9 | Camptothecin | 0.69 | 1 |
| 10 | Cytarabine | 0.69 | 1 |
| 11 | dihydrorotenone | 0.69 | 1 |
| 12 | Podophyllotoxin | 0.69 | 1 |
| 13 | streptonigrin | 0.69 | 1 |
| 14 | Trifluridine | 0.69 | 1 |
| 15 | Tripterygium | 0.69 | 1 |
About JAK2 as a Drug Target
JAK2 (Janus kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented JAK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
JAK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.